A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study☆

ESMO Open · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles